Previous genomewide association studies (GWASs) of AIDS have targeted end points based on the control of viral load and disease nonprogression. The discovery of genetic factors that predispose individuals to rapid progression to AIDS should also reveal new insights into the molecular etiology of the pathology.
Ϫ7
Ϫ6 Ϫ6
6.1 ϫ 10 P p 1.8 ϫ 10 P p 3.9 ϫ 10 TGFBRAP1 ( ; OR, 0.34). The haplotype analysis identified exonic and promoter SNPs potentially Ϫ6 P p 7 ϫ 10 important for PRMT6 and TGFBRAP1 function.
Conclusions. The statistical and biological relevance of these associations and their high ORs underscore the power of extreme phenotypes for GWASs, even with a modest sample size. These genetic results emphasize the role of the transforming growth factor b pathway in the pathogenesis of HIV-1 disease. Finally, the wealth of information provided by this study should help unravel new diagnostic and therapeutic targets.
genes involved in the control of viral load. Indeed, these 3 GWASs identified the HCP5 rs2395029 polymorphism, which is in linkage disequilibrium with HLA-B*57 and other immunity genes, such as MICB, TNF, LTB, BAT1, and HLA-C. An association with the HIV DNA level (reservoir) was also depicted by the PRIMO GWAS [2] for SDC2 (chromosome 8), whose encoded protein is required for Tat internalization. Finally, the ZNRD1 locus of chromosome 6 was associated with the control of disease progression but not of viral load in both the Euro-CHAVI (Center for HIV/AIDS Vaccine ImmunologyCenter for HIV/AIDS Vaccine Immunology) [3] and the nonprogressor Genomics of Resistance to Immunodeficiency Virus (GRIV) [4] GWASs.
To identify genetic loci predisposing a person to rapid progression of AIDS rather than disease control, we undertook a case-control GWAS involving a unique cohort of human immunodeficiency virus type 1 (HIV-1)-infected patients who experienced rapid progression, using Illumina HumanHap300 BeadChips. In a manner symmetric to the published nonprogressor GRIV GWAS [4] , the use of this extreme phenotype should lead to an enrichment of our knowledge of the genetic factors involved in rapid disease progression. The power of this extreme design has indeed been demonstrated by previous candidate gene studies [5] [6] [7] .
METHODS
The GRIV cohort. The GRIV cohort was established in France in 1995 to generate a large collection of DNA for genetic studies to identify host genes associated with either rapid progression or nonprogression to AIDS [5, 7] . Only white people of European descent living in France were eligible for enrollment to reduce confounding by population substructure. These criteria limit the influence of ethnic and environmental factors (all subjects live in a similar environment and are infected by B strains) and emphasize how the genetic makeup of each individual determines the various patterns of progression. Rapid progressors were included on the basis of the main clinical outcomes, CD4 T cell count and time to disease progression, and were defined as those who had 2 or more CD4 T cell counts below 300 cells/mm 3 within 3 years after the last seronegative test result. DNA was obtained from fresh peripheral blood mononuclear cells or from Epstein-Barr virus-transformed cell lines. The rapid progression group ( ) was n p 85 composed of 73 men and 12 women aged 21-55 years (median, 32 years) at inclusion. At inclusion, the median CD4 T cell count was 230 cells/mm 3 (minimum and maximum values, 20 and 297 cells/mm 3 ). All patients provided written informed consent before enrollment in the GRIV GWAS.
The seropositive control population. To discriminate between positive signals corresponding to either an association with rapid progression or an association with HIV-1 infection, we needed a group of seropositive control subjects who were not rapid progressors. For that, we used 275 white French subjects who qualified as nonprogressors to AIDS (ie, those who had an asymptomatic HIV-1 infection for 18 program was a 9-year follow-up study designed to clarify the development of insulin resistance syndrome. Subjects were recruited from 1994 to 1996 from volunteers insured by the French social security system, which offers periodic health examinations free of charge [9] . This second control group comprised 697 participants who were both not obese and normoglycemic from the D.E.S.I.R. trial, all French and HIV-1 seronegative. It was composed of 281 men and 416 women aged 30-64 years.
Genotyping method. The GRIV cohort and the 2 seronegative groups were genotyped using Illumina Infinium II HumanHap300 BeadChips (Illumina). Genomic DNA (750 ng) was whole-genome amplified, fragmented, denatured, and hybridized on prepared HumanHap300 BeadChips for a minimum of 16 h at 48ЊC. Non-specifically hybridized fragments were removed by washing, and the remaining specifically hybridized DNA was fluorescently labeled by a single base extension reaction and detected using a BeadArray scanner (Illumina). Normalized bead-intensity data obtained for each sample were loaded into BeadStudio software (version 3.1; Illumina), which converted fluorescence intensities into singlenucleotide polymorphism (SNP) genotypes.
Quality control. Using the BeadStudio software, we analyzed the crude genotyping data, and SNPs were filtered according to the following parameters. First, samples with a call rate (percentage of SNPs genotyped by sample) !95% in the Illumina clusters were deleted. Second, the SNPs with a call frequency (percentage of samples genotyped by SNP) !99% were reclustered. Third, after reclustering, samples with a call rate below 97% were deleted. The clustering step can create SNP genotyping errors, which can be prevented by following the Illumina procedure (see http://www.illumina.com/downloads/ GTDataAnalysis_TechNote.pdf). This method evaluates the quality of the newly created clusters according to several criteria, which can be manually checked and corrected as necessary. In total, 1300 SNPs were excluded by this Illumina quality control procedure. Finally, after all the quality control steps were performed, the 15,731 SNPs with a call frequency !98% (12% of missing data) were excluded. This procedure ensures reliable genotyping data with little missing data.
Hardy-Weinberg equilibrium analysis was performed for each SNP in each group by using an exact statistical test implemented in PLINK software ( [10] ; available at: http://pngu .mgh.harvard.edu/˜purcell/plink/). Deviation from Hardy-Weinberg equilibrium in a group of patients suggests that the SNP has a biological effect, while deviation in the control group or all groups suggests a systematic error in genotyping. The 1475 SNPs that were not in the Hardy-Weinberg equilibrium in the SU.VI.MAX control group ( ) were rejected in this Ϫ3 P ! 1.0 ϫ 10 way.
In total, 235 SNPs with low minor allelic frequency (!1%) in the global population were also filtered.
Haplotype inference. Haplotype inference was obtained using the rapid and accurate Shape-IT algorithm [11] .
Linkage disequilibrium. For each SNP exhibiting a significant association, we looked for the other SNPs in linkage disequilibrium ( ) in the HapMap population of Western 2 r у 0.8
European ancestry (CEU, HapMap data Release 21a/phase II, January 2007, on NCBI B35 assembly, dbSNP125; available at http://www.hapmap.org) to identify the genes possibly concerned by the associations. A SNP was assigned to a gene if it was located in the gene or in the 2 kb flanking regions (potential regulatory sequence); otherwise, it was considered intergenic. Statistical analysis. For each SNP, we performed a standard case-control analysis by using the Fisher exact test (with PLINK software) to compare allelic distributions between the rapid progressors and the control subjects.
To take into account the multiple tests while controlling for the risk of false discovery, we computed for each P value a false-discovery rate (FDR) under the form of a q value: the q value is an estimate of the proportion of false-positive signals below a threshold P value [12] . The FDR computation is more complex but more powerful than the standard Bonferroni corrections [13] [14] [15] , because it allows the identification of more true-positive signals. For polyfactorial diseases in which several genes are at stake, it thus provides a more adapted outlook on the GWAS results than the "all or nothing" Bonferroni cutoff. We thus used an FDR approach called local base estimating, with a 25% threshold for our case-control study.
For all the SNPs meeting this statistical threshold (Table 1 ), the quality of genotyping was individually rechecked with the BeadStudio software. We also checked that the allelic frequen- cies in the seropositive control population were similar to those in the seronegative SU.VI.MAX control population for those SNPs of interest, confirming that the observed associations were indeed linked to rapid progression.
Statistical reliability of the rapid progression results. The GRIV rapid progression cohort is unique, and no other independent cohort was readily available for replication. To check in an independent fashion the statistical relevance of the associations with rapid progression, we decided to evaluate the odds of obtaining just as many associations with the same statistical method (ie, the Fisher exact test and FDR cutoff) by comparing the genotypes of 1000 control subgroups (randomly extracted from the D.E.S.I.R. control cohort and composed of 85 subjects each) with the genotypes of the entire SU.VI.MAX control group. For each simulation, we counted the number of independent ( ) SNPs meeting the statistical threshold 2 r ! 0.5 of an FDR of 25% (Figure 1) .
Identification of population stratification. To correct for possible population stratification at the intercontinental level, case and control genotypes were analyzed using STRUCTURE software (version 2.2; see [16] and http://pritch.bsd.uchicago .edu/software.html). We selected a set of 328 SNPs informative for ancestral origin (F statistics fixation index, 10.2) based on the Perlegen data set and separated by 5 Mb to avoid linkage disequilibrium. We also included genotypes obtained from unrelated individuals representing the 3 populations studied by the HapMap project to better separate our rapid progressors and control individuals according to their continent of origin. While nearly all case and control subjects were within the range of the white individuals from HapMap, one individual was outside the white subjects cluster in the rapid progressors (decreasing the rapid progression group from 86 to 85 subjects).
To avoid spurious associations resulting from possible population stratification or genotyping errors, a quantile-quantile plot was also produced by plotting the ranked values of the test statistics against the approximated expected order statistic (Figure 2) . We also computed the genomic inflation factor l [17] . The result ( ), along with the quantile-quantile l p 1.038 plot, suggested little overall effect of stratification.
RESULTS
After the quality control tests, a total of 291,119 autosomal SNPs were tested for association with rapid progression. Figure  3 depicts the distribution of the P values along the chromosomes, and Table 1 presents the best signals (for an extended list, see Table 2 ). Eight associations with FDRs р25% were identified, corresponding to 6 independent ( ) SNPs.
2 r ! 0.5 Since no replication was readily available, we performed simulations on independent control populations to evaluate the reliability of these results (see Methods and Figure 1) . Overall, less than 1% of these tests yielded 6 or more independent signals with a FDR р25% (mean ‫ע‬ standard deviation p 0.4 ‫ע‬ 1.29), suggesting that most of the rapid progression associations found in this study are likely to be true positives. This result underscores the statistical relevance of the rapid progression associations, even with a modest sample size.
The best rapid progression signals were observed for SNPs on chromosome 1 (rs4118325 [ ] and rs10494056 To complete our analysis, we explored the influence of covariables-such as CCR5-D32 and CCR5-P1 haplotypes [7] , the HIV-1 infection mode (mucosal or parenteral), age at seroconversion, and sex-on all the associations presented in Table 1. None of them was found to affect the observed signals.
To deepen our genomic analysis, we also tried to combine our results with previously published data from the Euro-CHAVI cohort, which assessed the viral load end point [3] . We combined their P values with ours using the classical Fisher method. Unfortunately, no combined P values met the FDR threshold of 25% (data not shown; best combined P value, ). The lack of significant common signals between Ϫ5 6.23 ϫ 10 the 2 studies may likely stem from the difference in inclusion criteria, in particular the use of viral load versus the use of CD4 T cell count, and also from the elimination of very rapid progressors in the Euro-CHAVI study, since such patients could not exhibit a sufficiently prolonged viral load set point [3] . In the past, we have often observed that haplotypes may be more informative than individual SNPs; this was notably shown for CCR5 [7] , CXCR1 [6] , and HLA [5] . We thus decided to explore the haplotype patterns for the genes exhibiting the best signals in our rapid progression GWAS, limiting the investigation to exonic and promoter SNPs (Figure 4) . For PRMT6, we demonstrated that the effect of the PRMT6 SNP rs4118325 could be tracking a haplotype (composed of rs4118325 and rs2232016 [Ala135Val]) through linkage disequilibrium ( 2 r p , ) ( Figure 4A ). No differential messenger RNA 0.12 D' p 1 (mRNA) expression could be significantly associated with either of these SNPs using the Genevar database [18] or the Dixon database [19] .
For TGFBRAP1, the rs1020064 SNP was in high linkage disequilibrium ( ) with a haplotype containing 3 exon- Figure 4B ). The SNP rs2241797 (Arg275His) appeared to be essential, since the signal disappeared when that SNP was removed from the haplotype (P 1 ) and remained identical when either of the 2 syn-Ϫ2 5.0 ϫ 10 onymous SNPs were removed ( ). Interestingly,
Ϫ6
P p 1.62 ϫ 10 rs1020064 has been associated with differential expression of TGFBRAP1 in the Genevar database and of PPP2R3A [20] in the Dixon database ( Figure 5 ). More strikingly, in the Dixon database the nonsynonymous SNP rs2241797 was significantly associated with the differential expression of several proteins ( Figure 5 ), among which 4 have been independently described to interact with HIV-1 (MDN1 [21] , LRRFIP1 [22] , EIF5B [23] , and SFRS4 [24] ), and several have exhibited a positive association in an AIDS GWAS. Of note, no differential expression could be found for the 2 synonymous SNPs rs2241801 and rs12476720. For the SOX5 rs1522232 and RXRG rs10800098 SNPs, no haplotype involving exonic or promoter SNPs and no differential mRNA expression could be found.
DISCUSSION
For the first time, the extreme HIV-1 rapid progression phenotype was specifically examined in a GWAS. The power of using the GRIV extreme design has been demonstrated by previous candidate gene studies [5] [6] [7] 25] and by the previous GWAS of nonprogressors [4] . Here we have identified 6 novel associations with rapid progression with ORs as high as 4, emphasizing the power of this extreme design in spite of a relatively modest sample size. As a comparison, there was only 1 independent ( ) signal passing the FDR threshold of 2 r ! 0.5 25% in the GWAS of the nonprogressor GRIV cohort [4] . No replication was readily available, since this specific rapid progression design is rather unique in the world. The biological relevance of the rapid progression associations and their statistical validation through simulations with a second control group (!1% odds of finding as many independent signals) are nevertheless compelling. The use of an extreme population may provide a strong contrast and indeed help unravel new genetic factors, behaving as a magnifying glass [25, 26] .
Four of the 6 SNPs associated with rapid progression to AIDS were clearly linked to a gene (distance, !2 kb). SOX5 (OR, 0.45) encodes a transcription regulator notably expressed in lymph nodes and lymphoid tissues [27] and is also known to be involved in the transforming growth factor b (TGF-b)/ SMAD chondrogenesis signaling pathway [28, 29] . There is no other experimental evidence linking this protein to the pathogenesis of HIV-1 infection. RXRG (OR, 3.29) encodes a retinoic acid nuclear receptor mediating the antiproliferative effects of retinoic acid and is known to repress HIV-1 transcription and replication [30, 31] . Several studies have also associated vitamin A deficiency with a bad prognosis in patients with AIDS, but the benefit of vitamin A supplementation in AIDS patients is still controversial [32, 33] . The genetic association for PRMT6 (OR, 0.24) points toward a direct interaction between the host and the virus. Indeed, PRMT6 codes for an arginine N-methyltransferase previously reported to methylate HIV-1 Tat and Rev, impairing their function [34, 35] . The product of PRMT6 also methylates the high mobility group protein HMGA1, thereby modifying HMGA1 interactions with DNA [36] , which could alter HIV-1 integration into the human genome [37] . The modulation of PRMT6 transcription could thus affect HIV-1 integration or replication and prevent rapid progression. Finally, an association with rapid progression was discovered for TGFBRAP1 (OR, 0.34). TGFBRAP1 is expressed in most lymphoid tissues and is involved in the TGF-b signaling pathway [38] . TGF-b is a pleiotropic immunosuppressive cy-tokine involved in immune homeostasis and in the differentiation of and balance between type 17 T helper (Th17) cells (T cells protecting the mucosal barrier integrity [39] ) and regulatory T (T reg ) cells (T cells essential for immune suppression [40] ). Interestingly, recent works have also supported a combined role for TGF-b and retinoic acid for T reg cell differentiation [41, 42] . T reg cells are rapidly induced after simian immunodeficiency virus (SIV) and HIV-1 infection [43, 44] and may have a deleterious effect during the chronic phase of infection [45, 46] . Moreover, an impairment in the balance between Th17 and T reg cells during HIV-1 infection was recently described [40, 47, 48] . Finally, TGF-b can stimulate HIV-1 Tat transcription [49] and, reciprocally, be induced by Tat early during infection [50] , supporting a key role for the intermingled effects of TGF-b and Tat in the early development of HIV-1 infection. Overall, our results support the central role played by the TGF-b pathway and the balance between Th17 and T reg cells in AIDS progression. Interestingly, PRMT6 and TGFBRAP1 haplotypes involving promoter and exonic SNPs were also associated with disease progression; moreover, some of the haplotype SNPs could be associated with downstream differential mRNA expression ( Figure 5 ).
In conclusion, as for all genetic studies, our results-including SNPs with higher P values, which were not discussedwill need to be confirmed by replication in other cohorts and by other investigations, such as fine gene mapping and biological experiments.
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